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but also appear to have been selected for
autoreactive clones! It remains to be elucidated
whether cellular senescence in the context
of TPPII deﬁciency is a direct and cell-intrinsic
event and how its molecular mechanism
relates to similar immunosenescencephenotypes
observed in recently discovered primary
immunodeﬁciencies associated with immune
cytopenia, eg, as deﬁciency of the vesicle-
trafﬁcking– and autophagy-linked
lipopolysaccharide-responsive beige and
anchor-containing (LRBA) protein,
haploinsufﬁciency of cytotoxic T-lymphocyte
antigen 4 (CTLA4), gain of function of
phosphatidylinositol-3-OH kinase (PI(3)K)
p110delta or loss of PI(3)K p85alpha, or
deﬁciency of serine threonine kinase 4 (STK4;
see ﬁgure).4-7 Recently, a senescence-like
disturbance of T-cell development was
also reported in the paramount example
of autoimmune cytopenia in PID, ie,
autoimmune lymphoproliferative syndrome
(ALPS) due to Fas deﬁciency.8 It is not clear
if immunosenescence serves as a sufﬁcient
cause of autoimmune cytopenia. An array
of mechanisms which are not linked to
immunosenescence may contribute to
the cytopenia in PID. These include
a tipped balance between TH17 and
regulatory T cells, most recently reported in
gain-of-function mutations of signal transducer
and activator of transcription 3,9 several
syndromes of immune dysregulation and
hemophagocytosis, syndromes of bonemarrow
failure, and secondary myelosuppression
(reviewed in Seidel10). Thus, detection of
markers of immunosenescence should be
considered a valuable tool that, in addition
to the determination of naive T cells, will
support the immune phenotypic differential
diagnosis. Although not routine, this should
be feasible in many laboratories. When done
in suspected PID, it should be of particular
interest in the context of autoimmune
cytopenias of childhood. A pertinent catalog
of diseases will also pave the way to clarifying
the signaling pathways that underlie
immunosenescence and autoimmune
cytopenia. The ﬁgure provides a sketch of
candidate pathways that may be targeted
by small compounds or antibodies. It is safe
to assume that eventually, patients with
chronic immune cytopenias will be the
beneﬁciaries of these investigations.
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In this issue of Blood, Peffault de Latour et al describe ex vivo measurements
of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients
on eculizumab treatment. This is the ﬁrst systematic pharmacodynamic (PD)
study of eculizumab in PNH patients which shows that CH50 is a promising
biomarker of therapeutic complement blockade.1
Impaired blood cell surface complementregulation is the hallmark of PNH,
eventually accounting for its typical
complement-mediated intravascular anemia.2
The anti-C5 monoclonal antibody eculizumab
has drastically changed the landscape of
PNH treatment; indeed, eculizumab has been
proven effective in controlling intravascular
hemolysis of PNH, resulting in the resolution
of all hemolysis-related symptoms and in the
reduction or even abolishment of the need for
red blood cell (RBC) transfusions.3 Long-term
treatment with eculizumab seems to reduce
the risk of thromboembolic events,2,4
eventually leading to a signiﬁcant improvement
of survival.5 Nevertheless, the majority of
PNH patients on eculizumab continue to
exhibit mild to moderate anemia,2 and even
patients achieving normal hemoglobin levels
show increased reticulocyte counts, consistent
with residual hemolysis.6 Thus, one may
question how this is related to pharmacology of
eculizumab. Available PD data on eculizumab
are limited to the ﬁrst 11 patients enrolled in
the pilot study; in this study, the authors used
a chicken RBC-based complement hemolytic
assay, showing that full complement blockade
was achieved in all patients with sustained
pharmacologic levels of eculizumab.7 In the
routine practice, no assay is available to monitor
complement activity, and physicians may track
therapeutic complement inhibition by using
downstream biomarkers of hemolysis, such as
lactate dehydrogenase (LDH), haptoglobin,
bilirubin, and hemoglobinuria/hemosiderinuria.
Here Peffault de Latour et al report on
a systematic PD study on 22 PNH patients on
eculizumab, in which complement activity
has been investigated by a standard hemolytic
complement assay (CH50), in combination
with free eculizumab dosage and other routine
laboratory testing. The main ﬁnding of their
study is that CH50 is a reliable biomarker of
complement activity that may be used to
track pharmacologic efﬁcacy of complement
inhibition. Furthermore, CH50 strongly
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correlates with free eculizumab levels,
providing evidence that these 2 biomarkers
are adequate for monitoring anticomplement
treatment in PNH. Of the 22 patients whowere
longitudinally analyzed, incomplete C5
blockade was demonstrated in about half of the
samples (see ﬁgure). Indeed, in the total of
364 samples, full blockade of CH50 was
associatedwith lowerLDH levels, showing that
CH50 is a sensitive and instant marker of in
vivo residual complement activity, which
in PNH eventually results in detectable
hemolysis. The correlation of CH50 with
other laboratory measures of intravascular
hemolysis (hemoglobin, reticulocytes, and
bilirubin) was less evident than that with
LDH (but few patients have been included),
likely because the former are less instant
markers of intravascular hemolysis (and they
may also be affected by other conditions,
such as extravascular hemolysis and marrow
failure). CH50 correlates with free eculizumab
levels; indeed, higher free eculizumab was
associated with full CH50 blockade. However,
free eculizumab level does not correlate with
LDH, whereas it was associated with elevated
bilirubin and need for RBC transfusions.
These observations suggest that CH50 is the
best PD measure to track instant complement
blockade, whereas free eculizumab level
represents the best pharmacokinetic (PK)
measure to predict propensity to develop
leaks in pharmacologic complement inhibition.
Neither CH50 nor free eculizumab shows any
correlation with C3 deposition, which was
documented in all PNHpatients on eculizumab,
as previously reported.6
This study documents that PKs and PDs
of eculizumab in PNH are not entirely
predictable and eventually heterogeneous
among patients; the actual clearance
mechanism of both free and C5-bound
eculizumab has not been described yet.
Notably, whereas low circulating levels were
obviously associated with lack of complement
blockade, residual complement activity may
be detected even in the presence of an excess
of free eculizumab. This ﬁnding parallels the
observation that pharmacologically effective
levels of eculizumab are not able to fully
prevent hemolysis in an in vitro extended
acidiﬁed serum assay (which tests the
functional activity of the alternative
activating and terminal effector complement
pathways).8,9 In this assay, even the in vitro
addition of an excess of eculizumab does not
revert this residual lytic complement activity
(unpublished data). The reasons and the
meaning of these observations remain to be
elucidated, even if it is reasonable to think
that they may reﬂect the incapability of
eculizumab in facing an excess of complement
activation as it may occur in vitro or in vivo.
Indeed, hemolytic crises are commonly
observed during infections, eventually as
a consequence of an extra activation of the
complement cascade; because these crises may
occur irrespective of eculizumab levels, they
should be described as a PD rather than PK
Detection of residual complement activity in PNH patients on eculizumab, with their pathogenic and therapeutic implications. (A) Residual CH50 activity in PNH on eculizumab (see
Figure 2A in the article by Peffault de Latour et al that begins on page 775). (B) Mechanism of residual intravascular hemolysis on eculizumab: lack of complete C5 blockade may be
due to low plasma level of eculizumab (PK breakthrough) and extra complement activation (PD breakthrough) or rare C5 polymorphisms. Residual intravascular hemolysis may
benefit from changes in eculizumab schedule and novel terminal complement inhibitors.10 (C) Mechanism of supervening extravascular hemolysis: due to the lack of CD55, proximal
complement activation on RBC remains impaired, eventually leading to C3 opsonization and subsequent C3-mediated extravascular hemolysis.6 C3-mediated extravascular
hemolysis may benefit from novel inhibitors of the proximal complement targeting C3 and other proteins involved in the activation of the complement alternative pathway.8-10
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breakthrough. It has to be remarked that an
excellent clinical efﬁcacy can be achieved
irrespective of this residual complement
activity, eventually raising the question
whether the abolishment of this residual
activity is a goal to be pursued for improving
the results of current anticomplement
treatment.
With their study, Peffault de Latour et al
provide a reliable way to monitor therapeutic
complement inhibition. Given that residual
anemia in PNH patients on eculizumab may be
due to different (but possibly concomitant)
causes (residual intravascular hemolysis
due to PK or PD breakthrough, bone
marrow failure, C3-mediated extravascular
hemolysis),10 these ﬁndings are useful to drive
therapeutic decisions (see ﬁgure). Indeed, only
PNH patients showing recurrent residual
CH50 activity may beneﬁt from modiﬁcation
of the treatment schedule (ie, increased doses
or reduced administration intervals). This
mechanistic demonstration of residual terminal
complement activity is extremely interesting
even in the context of the development of
second-generation complement inhibitors.
Indeed, a number of novel complement
therapeutics are in preclinical and clinical
investigations8-10; they may intercept
complement at the level of its terminal effector
components (eg, C5 inhibitors) or target the
proximal activating complement. The latter
include broad C3 inhibitors (eg, compstatin)9
and pathway-speciﬁc modulators of the initial
complement activation (eg, alternative pathway
inhibitors targeting complement factor B and
factor I, or factor H-based engineered proteins).8
In the future scenario of a multioption
complement inhibition, the assays proposed by
Peffault de Latour et al will be pivotal to identify
patients who may beneﬁt from a second-line
treatment with other terminal complement
inhibitors and patients who better qualify for an
upstream targeted intervention aiming to treat
C3-mediated extravascularhemolysis (seeﬁgure).
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The off-target effects of
nonspecific NK cells
-----------------------------------------------------------------------------------------------------
Dean A. Lee MD ANDERSON CANCER CENTER
In this issue of Blood, Shah et al describe the onset of severe acute graft-
versus-host disease (GVHD) in 5 of 9 patients who received infusions of ex
vivo expanded donor natural killer (NK) cells after HLA-matched hematopoietic
stem cell transplantation (HSCT).1
Despite conducting a small phase 1 trialwith signiﬁcant diversity in patients,
donors, products, and treatment, the authors
provide careful correlative studies that suggest
exacerbation of subclinical T-cell–mediated
skin and gut graft-versus-host as a possible
mechanism. By carefully evaluating the
manufacturing process, characteristics of
the NK-cell and stem cell products, and
patient pathology, the authors demonstrate
a previously unrecognized potential for NK
cells to have a profound effect in promoting
GVHD in this context.
This clinical trial used CD34 selection
and CD3 depletion of the starting apheresis
product to deliver a very low dose of T cells
in both the stem cell graft and NK cell
product, enabling a posttransplant period
without immune-suppressive drugs that
would interfere with NK-cell function.
T-cell doses were ,23 104/kg in the stem
cell graft and,2 3 103/kg in the NK-cell
infusion. NK-cell doses were also very low
compared with previously published trials;
subjects received only 105 to 106/kg.
That NK cells can discriminate between
healthy and malignant cells despite lacking
antigen speciﬁcity, separating graft-versus-
leukemia (GVL) from GVHD, is especially
striking in the setting of HLA mismatch,
where NK cells appear to have the most
pronounced effect. More strikingly, NK
cells may mediate a GVL effect while
simultaneously mediating a decrease in
GVHD, perhaps because missing self alone
is insufﬁcient, and normal tissues do not
express the requisite activating ligands to
induce an NK-cell response. Genetic
determinants of NK-cell function may
have value in predicting GVHD in the
transplant setting,2,3 but rapid NK-cell
reconstitution4 and higher NK-cell graft
content5 are associated with decreased
GVHD. Moreover, hundreds of patients
treated in clinical trials infusing NK cells
derived by apheresis and T-cell depletion have
shown no infusion-related dose-limiting
toxicity or evidence of GVHD exacerbation,
whether delivered after high-dose
chemotherapy6 or after mismatched HSCT.7
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